申请人:Synthelabo
公开号:US04794185A1
公开(公告)日:1988-12-27
A process for the preparation of an imidazopyridine which is a compound of formula (I) ##STR1## in which: Y denotes hydrogen, a halogen or a C.sub.1-4 alkyl group; X.sub.1 and X.sub.2 denote, independently of each other, hydrogen, a halogen or a C.sub.1-4 alkoxy, C.sub.1-6 alkyl, CF.sub.3, CH.sub.3 S, CH.sub.3 SO.sub.2 or NO.sub.2 group; and R.sub.1 and R.sub.2 denote, independently of each other, hydrogen or a C.sub.1-5 alkyl group, with the proviso that R.sub.1 and R.sub.2 do not both denote hydrogen, or a salt thereof; which process comprises reacting a compound of formula (V) ##STR2## wherein Y, X.sub.1, X.sub.2, R.sub.1 and R.sub.2 are as defined above, with a reducing agent and if desired converting the resulting compound of formula (I) into a salt, together with intermediates of formulae: ##STR3## The final products have useful pharmacological properties, e.g. as anxiolytics.
一种制备咪唑吡啶的方法,该咪唑吡啶是化合物的结构式(I) ##STR1## 其中:Y代表氢、卤素或C.sub.1-4烷基基团;X.sub.1和X.sub.2独立地代表氢、卤素或C.sub.1-4烷氧基、C.sub.1-6烷基、CF.sub.3、CH.sub.3 S、CH.sub.3 SO.sub.2或NO.sub.2基团;R.sub.1和R.sub.2独立地代表氢或C.sub.1-5烷基基团,但R.sub.1和R.sub.2不同时代表氢,或其盐;该方法包括将结构式(V) ##STR2## 中的化合物与还原剂反应,如果需要,将得到的结构式(I)化合物转化为盐,其中Y、X.sub.1、X.sub.2、R.sub.1和R.sub.2如上定义,并包括中间体的结构式: ##STR3## 最终产物具有有用的药理特性,例如作为抗焦虑剂。